(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 May 2011 (19.05.2011)

PCT

(10) International Publication Number
WO 2011/057788 A1

(51) **International Patent Classification**:
C07K 16/28 (2006.01) ***A61P 35/00*** (2006.01)
C07K 14/705 (2006.01) ***A61K 39/395*** (2006.01)

(21) **International Application Number**:
PCT/EP2010/006888

(22) **International Filing Date**:
11 November 2010 (11.11.2010)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:

09014136.7	11 November 2009 (11.11.2009)	EP
61/260,202	11 November 2009 (11.11.2009)	US
10006956.6	6 July 2010 (06.07.2010)	EP
61/361,618	6 July 2010 (06.07.2010)	US

(71) **Applicants** *(for all designated States except US)*: **GANYMED PHARMACEUTICALS AG** [DE/DE]; Freiligrathstrasse 12, 55131 Mainz (DE). **JOHANNES GUTENBERG-UNIVERSITÄT MAINZ** [DE/DE]; Saarstrasse 21, 55128 Mainz (DE).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **SAHIN, Ugur** [TR/DE]; Philipp-von-Zabern-Platz 1, 55116 Mainz (DE). **TÜRECI, Özlem** [DE/DE]; Philipp-von-Zabern-Platz 1, 55116 Mainz (DE). **KOSLOWSKI, Michael** [DE/DE]; Autogenstrasse 50, 65933 Frankfurt (DE). **WALTER, Korden** [DE/DE]; Hüglerstrasse 3, 65203 Wiesbaden (DE). **WÖLL, Stefan** [DE/DE]; Pommardstrasse 22a, 55299 Nackenheim (DE). **KREUZBERG, Maria** [DE/DE]; Freiherr-vom-Stein Strasse 1, 55131 Mainz (DE). **HUBNER, Bernd** [DE/DE]; Thelottstrasse 14, 80933 München (DE). **ERDELJAN, Michael** [DE/DE]; Hintergasse 60, 65239 Hochheim am Main (DE).

(74) **Agents**: **VOSSIUS, Volker** et al.; Geibelstrasse 6, 81679 München (DE).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2011/057788 A1

(54) **Title**: ANTIBODIES SPECIFIC FOR CLAUDIN 6 (CLDN6)

(57) **Abstract**: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing Claudin-6 (CLDN6), including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.